Expression of Serum miR-155 in Children with Mycoplasma pneumoniae Pneumonia and Its Role in Immunity to Mycoplasma pneumoniae
Authors Jin Y, Xue J, Ruan M, Lu J, Xu Q, Shi Y, Yu F
Received 17 August 2020
Accepted for publication 10 February 2021
Published 29 March 2021 Volume 2021:14 Pages 1273—1281
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Editor who approved publication: Dr Héctor M. Mora-Montes
Yue Jin, Jie Xue, Mengran Ruan, Jinxing Lu, Qian Xu, Yuanyuan Shi, Fei Yu
Department of Pediatrics, Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang, 223600, Jiangsu, People’s Republic of China
Correspondence: Yue Jin
Department of Pediatrics, Affiliated Shuyang Hospital of Xuzhou Medical University, No. 9, Yingbin Road, Shucheng Town, Shuyang, 223600, Jiangsu, People’s Republic of China
Email [email protected]
Objective: To investigate the expression of serum miR-155 in children with Mycoplasma pneumoniae pneumonia (MPP).
Methods: A total of 100 children at our hospital with pneumonia caused by Mycoplasma pneumoniae infection were enrolled as a study group, including 45 cases in the acute phase (acute phase group) and 55 in the recovery phase (recovery phase group). An additional 30 healthy children were enrolled during the same period as the control group. The expression levels of miR-155, tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), IL-10, IL-13, immunoglobulin (Ig) G, IgA, complements (C3 and CH50), and T lymphocyte subsets (CD3+, CD4+, CD8+, and CD4+/CD8+) were determined. Multivariate logistic regression analysis was performed to identify risk factors affecting MPP in children.
Results: miR-155, IL-10, IgG, IgA, CD3+, CD4+, and CD4+/CD8+ were poorly expressed in children with MPP, and their expression in the acute phase group was significantly lower than that in the recovery phase group. TNF-α, IL-13, C3, and CH50 were highly expressed in the children, and their expression was significantly higher in the acute phase group than in the recovery phase group. In the acute phase group, the expression of IL-8 was significantly higher than that in the control and recovery phase groups but without any significant differences between the recovery phase and control groups. Age, season, low complement state, epidemiological contact history, and antibiotic use time were independent risk factors affecting MPP in children.
Conclusion: Serum miR-155 is poorly expressed in children with MPP, and it can regulate inflammatory disorders and immune responses.
Keywords: miR-155, Mycoplasma pneumoniae, immunity, inflammation, risk factors
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]